28997-31-1

Usage

InChI:InChI=1/C14H12N4O4/c1-9-15-8-12(18(21)22)16(9)6-7-17-13(19)10-4-2-3-5-11(10)14(17)20/h2-5,8H,6-7H2,1H3

Upstream product

• 136918-14-4 phthalimide 
• 443-48-1 metronidazole 
• 1074-82-4 potassium phtalimide 
• 13182-81-5 1-(2-chloroethyl)-2-methyl-5-nitro-1H-imidazole 

Downstream Products

• 55881-33-9 1-(2-aminoethyl)-2-methyl-5-nitro imidazole 

Relevant academic research and scientific papers

DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF

The invention relates to dendritic compounds comprising a chelating, fluorochrome or recognition agent of formula (I), to compositions comprising same, and to uses thereof, wherein in said formula (I): T, L1, D, R, L2, V and n are as defined in the description.

Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole 99mTc-complexes as potential agents for targeting hypoxia

With the aim to develop new potential 99mTc-radiopharmaceuticals for imaging hypoxia based on the formation of Tc-nitrido complexes, two novel dithiocarbamate containing metronidazole derivatives (L1 and L2) have been prepared and characterised. The synthesis of L1 and L2 was achieved in excellent yield and high purity. Labelling with 99mTc was successfully performed using a low ligand concentration (approximately 2-3 mg) and the desired products were obtained with high radiochemical purity (>90%). Lipophilicity, plasma protein binding, and biodistribution in normal- and tumour-bearing-CD1 mice studies were performed to asses the potentiality for nuclear medicine oncology. According to the physicochemical and biological behaviour both in healthy animals and in animals bearing solid tumours complex dtcTc1 could be considered as a starting point for the development of new radiopharmaceuticals for imaging hypoxia.

N-[2-(nitro-1-imidazolyl)ethyl]naphthal imides

Imides having a nitroimidazolylethyl group as a N-substituent are described herein. They are anti-bacterial and anti-protozoal agents. The compounds are prepared by the reaction of the appropriate imide with the chloroethylimidazole or with the tosylate or mesylate of the corresponding hydroxyethyl compound.